Collectively, these results indicated that the switch to CHRNA5[AluSz] expression we observed in cancer would severely compromise the levels of canonical CHRNA5 that would otherwise be produced and, in turn, reduce the pro-tumour effects of CHRNA5 expression. The gene discussed is CHRNA5; the disease is neoplasm.